



Civica Advances Its Mission by Expanding Member Base and Product Offerings

Company added 5 new members in 2025 and introduced new products based on member input

LEHI, UT – January 27, 2026 – Civica, a nonprofit pharmaceutical company formed to help provide a sustained supply of essential generic medicines to hospitals across the United States provided a 2025 business update today.

“In 2025, we continued to expand Civica’s impact to the U.S. healthcare system, by adding new members and offering new products,” said Jennifer Spalding, Chief Commercial Officer, Civica. “These include essential medicines at risk of shortage, putting pressure on health care providers to find a substitution. We are especially pleased to have been able to supply lorazepam injection without interruption to our members, as this drug has been on shortage or restricted supply for over 10 years. Our model helps our members focus on providing care to their patients.”

New members who joined Civica in 2025 include Inova Health; the Alaskan Native Tribal Health Consortium (ANTHC); Allina; Avera and Dartmouth Mary Hitchcock Memorial. In total, these systems represent more than 6,000 hospital beds.

Under the Civica model, hospitals enter market-stabilizing contracts directly with the company, avoiding middlemen players. Doctors and pharmacists at member hospitals choose the drugs that Civica provides. Civica offers all members the same cost-plus price for these products, regardless of hospital size, and strives to provide 6 months of buffer inventory. Further, the company prioritizes U.S.-based suppliers, helping to ensure high-quality products.

In addition to adding new members, Civica expanded product offerings to its members in 2025. Civica now offers more than 70 generic sterile injectables, many of which are used in urgent care settings to address serious, and sometimes life-threatening, health issues.

A recent report from the American Society of Health System Pharmacists¹ shows that while the number of drug shortages in the United States has declined from an all-time high in 2006, that the impact of these shortages continue to challenge health care providers.

According to the American Hospital Association², when drug shortages occur, hospitals use staff time to find, procure and administer alternative drugs. When a particular drug needed by a patient is unavailable, hospitals must find other suppliers, renegotiate contracts and undergo additional training to ensure medication safety using alternative therapies.

“Joining Civica has strengthened Essentia Health’s pharmaceutical supply chain and ensured our ability to continue meeting the needs of our patients who entrust us with their care,” said David Sperl, PharmD, Senior Director, Acute Care Pharmacy, Essentia Health.

About Civica

Founded in 2018 by innovative healthcare leaders nationwide, Civica is a pharmaceutical nonprofit dedicated to ensuring the accessibility, affordability and quality of essential generic injectables and biosimilar insulins. With 60 members, including leading health systems, hospitals, and philanthropic organizations, Civica supplies more than 70 essential medicines to over 1,400 hospitals, supporting care for nearly 95 million patients. By committing to long-term contracts and targeting six months of safety stock, we help stabilize the market and reduce the impact of shortages.

Hospitals of any size can benefit from being a member of Civica. The company’s current list of offerings can be found here: [Medications | Civica Rx | Essential sterile injectable medications and affordable insulin biosimilars](#)

[Contact Civica](#) for more information on how to become a member.

#####

¹ [Drug Shortages Statistics - ASHP](#)

² [Drug Prices and Shortages Jeopardize Patient Access to Quality Hospital Care | AHA News](#)